Skip to content

Safety and Efficacy of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke

Safety and Efficacy of Remote Ischemic Conditioning Combined With Intravenous Thrombolysis for Acute Ischemic Stroke: A Multicenter, Randomized, Parallel-controlled Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04980625
Enrollment
558
Registered
2021-07-28
Start date
2021-07-01
Completion date
2023-05-11
Last updated
2024-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Brief summary

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.

Detailed description

In this study, 558 cases of ischemic stroke who undergo intravenous thrombolysis within 4.5 hours from the onset are included in 18 centers in China according to the principle of random, and parallel control. The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days. The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day for 7 consecutive days. Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning combined with intravenous thrombolysis in treating acute ischemic stroke.

Interventions

PROCEDURERemote ischemic conditioning

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg.

PROCEDURESham remote ischemic conditioning

Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg.

Sponsors

Yi Yang
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) Age≥18 years, regardless of sex; * 2\) Patients with a clinically definite diagnosis of acute ischemic stroke and undergo intravenous thrombolysis with alteplase; * 3\) Pre-thrombolysis NIHSS \>= 4, and \<= 24; * 4\) Premorbid mRS 0-1; * 5\) Signed and dated informed consent is obtained;

Exclusion criteria

* 1\) Patients who have the contraindication of intravenous thrombolysis with alteplase. * 2\) The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. * 3\) Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc. * 4\) Pregnant or lactating women. * 5\) Severe hepatic and renal dysfunction. * 6\) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons. * 7\) Unwilling to be followed up or treated for poor compliance. * 8\) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission. * 9\) Other conditions that the researchers think are not suitable for the group.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with Modified Rankin Scale (mRS) Score 0-13 monthsProportion of patients with Modified Rankin Scale (mRS) Score 0-1. Ranged from 0 to 6, a low value represents a better outcome.

Secondary

MeasureTime frameDescription
Barthel Index (BI) at 24 hours, and 7 days after IVT.24 hours, 7 daysBarthel Index (BI) at 24 hours, and 7 days after IVT. Ranged from 0 to 100, a high value represents a better outcome.
Proportion of patients with modified Rankin Scale (mRS) Score 0-2 at 90±3 days after IVT.90±3 daysProportion of patients with modified Rankin Scale (mRS) Score 0-2 at 90±3 days after IVT. mRS: Ranged from 0 to 6, a low value represents a better outcome.
Frequency of adverse events during follow-up90 daysAll adverse events through 90 days.
National Institute of Health stroke scale (NIHSS) at 24 hours, and 7 days after IVT.24 hours, 7 daysNational Institute of Health stroke scale (NIHSS) at 24 hours, and 7 days after IVT. Ranged from 0 to 42, a low value represents a better outcome.
Mortality within 90 days.90 daysMortality within 90 days.
Stroke recurrence rate within 90 days.90 daysStroke recurrence rate within 90 days.
Frequency of Hemorrhagic transformation within 24 hours after IVT.24 hoursFrequency of Hemorrhagic transformation within 24 hours after IVT.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026